Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.APHB · Entity 6329 | Director · Chief Executive Officer | April 01, 2017 | April 04, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date April 01, 2017 · Filed April 04, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2021-03-31 | Direct | 214,214 |
Reported balance
After 2017-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-04-01 · Grant · Acquired 214,214 · Balance 214,214 F1: The shares subject to the option are 100% vested and exercisable as of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option are 100% vested and exercisable as of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2017 Filed Apr 4, 2017 21:33 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 214,214 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001209191-17-025160 · doc4.xml · derivative · entry 1 Salka Michael Scott · CIK 0001542981 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,214 Underlying: Common Stock · 214,214 shares Expires 2021-03-31 F1 · derivative.exercise_date: The shares subject to the option are 100% vested and exercisable as of the date of grant. Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 20:57 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantCommon Stock | 7,000 | $0.39 | $2,730.00 |
DisclosureSEC source: 0001209191-16-154877 · doc4.xml · nonDerivative · entry 1 Salka Michael Scott · CIK 0001542981 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,200 F1 · timeliness: These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.